Zhou, Xinna <br/><br/>
Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.  [electronic resource] 

 -  International journal of clinical pharmacology and therapeutics  Nov 2015 
 - 914-22 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0946-1965 
<br/><br/><label>Standard No.: </label>10.5414/CP202391  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Antineoplastic Agents, Alkylating--adverse effects<br/>Biotransformation<br/>Breast Neoplasms--drug therapy<br/>Chi-Square Distribution<br/>China<br/>Cytochrome P-450 CYP2B6--genetics<br/>Cytochrome P-450 CYP3A--genetics<br/>Disease Progression<br/>Disease-Free Survival<br/>Female<br/>Genotype<br/>Glutathione S-Transferase pi--genetics<br/>Humans<br/>Logistic Models<br/>Middle Aged<br/>Multivariate Analysis<br/>Neoplasm Metastasis<br/>Odds Ratio<br/>Patient Selection<br/>Pharmacogenetics<br/>Phenotype<br/>Polymorphism, Single Nucleotide<br/>Retrospective Studies<br/>Risk Factors<br/>Salvage Therapy<br/>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization<br/>Thiotepa--adverse effects<br/>Time Factors<br/>Treatment Outcome<br/>Triethylenephosphoramide--adverse effects